Black Diamond Therapeutics (BDTX) vs Zura Bio (ZURA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Black Diamond Therapeutics (BDTX) has outperformed Zura Bio (ZURA) over the past year, losing 65.5% versus a loss of 74.4%. Zura Bio is the larger company by market cap ($89.6 million vs $75.3 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BDTX | ZURA |
|---|---|---|
| Share price | $1.31 | $0.9305 |
| Market cap | $75.28M | $89.63M |
| 1-day change | -5.76% | -2.30% |
| YTD return | -46.09% | -82.24% |
| 1-year return | -65.53% | -74.37% |
| 5-year return | -79.30% | — |
| EPS (TTM) | $-0.77 | $-1.11 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $70.00M | — |
| Net income (latest FY) | $22.37M | $-68.65M |
| Operating margin | 17.89% | — |
| Net margin | 31.95% | — |
| 52-week high | $3.97 | $7.44 |
| 52-week low | $1.31 | $0.919 |
| Distance from 52-week high | -67.00% | -87.49% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +663.36% | +759.75% |
| Average volume | 697.70K | 4.47M |
| Shares outstanding | 57.47M | 96.33M |
| Employees | 21 | 40 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Black Diamond Therapeutics
BDTX stock →Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 21 employees
About Zura Bio
ZURA stock →Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 40 employees
BDTX vs ZURA FAQ
Which is bigger, Black Diamond Therapeutics or Zura Bio?
Zura Bio (ZURA) is larger, with a market capitalization of $89.63M compared with $75.28M for Black Diamond Therapeutics (BDTX).
Which stock has performed better over the past year, BDTX or ZURA?
BDTX returned -65.53% over the past 12 months, compared with -74.37% for ZURA (price return, excluding dividends). Past performance does not predict future results.
Are Black Diamond Therapeutics and Zura Bio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.